Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

3articles mentioning institutions

6institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: BASECAMP-1 ×

BASECAMP-1

This institution is selected. Its supporting articles are shown below.

BASECAMP-13

Articles mentioning BASECAMP-1

3 articles · page 1 of 1

BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials

bmjonc · full text · 2026-03-27 · 4 matching annotations

91.3%

BASECAMP-1 Tempus Tempus AI, Inc tumour-associated HLA-A*02 LOH Tmod DENALI-1

…ociated with response and durable remissions.18–20Third, within BASECAMP-1, there is ongoing real-world data collection for patients with …

535 EVEREST-2: a phase 1/2 study of A2B694, a logic-gated Tmod CAR T therapy to treat solid tumors expressing mesothelin (MSLN) with HLA-A*02 loss of heterozygosity: initial safety and efficacy results

jitc · abstract · 2025-11-04 · 1 matching annotations

75.2%

A2 Bio BASECAMP-1 A2B694 NSCLC pembrolizumab dexamethasone carboplatin

…ses, data managers, and apheresis teams at each study site; and A2 Bio. Medical writing support was provided by Jennifer M. Kulak, PhD…

585 DENALI-1: a seamless phase 1/2 study of A2B395, a logic-gated, allogeneic, Tmod CAR T therapy, in patients with EGFR-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity

jitc · abstract · 2025-11-04 · 1 matching annotations

77.6%

A2 Bio BASECAMP-1 A2B395 solid tumors A2B530 hematologic malignancies graft-vs-host disease

…ses, data managers, and apheresis teams at each study site; and A2 Bio. Medical writing support was provided by Jennifer M. Kulak, PhD…